Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag.filedCriticalF.Hoffmann-La Roche Ag.
Publication of YU9302ApublicationCriticalpatent/YU9302A/sh
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Primena terapeutski efektivne količine IFN-A ili PEG1IFN-α u kombinaciji sa terapeutski efektivnom količinom farmaceutski prihvatljive soli ili proleka mikofenolatske kiseline, za proizvodnju medikamenata za terapiju pacijenata obolelih od bolesti jetre. Komponente se primenjuju tokom perioda vremena koji je dovoljan da umanji količinu HCV-RNK prisutne u perifernoj krvi naznačenog pacijenta na nivo od manje od 100 kopija(ml, 24 nedelje nakon završetka terapije.[The use of therapeutically effective amount of IFN- α or PEG-IFN-α in association with a therapeutically effective amount of a pharmaceutically acceptable salt or prodrug of mycophenolic acid for the manufacture of medicaments for treating liver diseases patients. The components are administered over a period of time at least sufficient to reduce the amount of HCV-RNA present in the peripheral blood of said patient to less than 100 copies/ml at 24 weeks after the end of treatment.
YU9302A1999-08-132000-08-08Mikofenolat mofetil u kombinaciji sa peg-ifn-alfa
YU9302A
(sh)
Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma